{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T21:47:08Z","timestamp":1770155228291,"version":"3.49.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Clinical Sleep Medicine"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.5664\/jcsm.11182","type":"journal-article","created":{"date-parts":[[2024,4,23]],"date-time":"2024-04-23T15:00:38Z","timestamp":1713884438000},"page":"1467-1477","source":"Crossref","is-referenced-by-count":2,"title":["Effectiveness and optimization of low-sodium oxybate in participants with narcolepsy switching from a high-sodium oxybate: data from the Substitution of Equal Grams of Uninterrupted Xyrem to Xywav study"],"prefix":"10.1007","volume":"20","author":[{"given":"Wayne","family":"Macfadden","sequence":"first","affiliation":[{"name":"Jazz Pharmaceuticals, Philadelphia, Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eileen B.","family":"Leary","sequence":"additional","affiliation":[{"name":"Jazz Pharmaceuticals, Palo Alto, California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas S.","family":"Fuller","sequence":"additional","affiliation":[{"name":"Jazz Pharmaceuticals, Philadelphia, Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. Todd","family":"Kirby","sequence":"additional","affiliation":[{"name":"Jazz Pharmaceuticals, Philadelphia, Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asim","family":"Roy","sequence":"additional","affiliation":[{"name":"Ohio Sleep Medicine and Neuroscience Institute, Dublin, Ohio"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccm.2010.02.014"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1500587"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.5664\/jcsm.9328"},{"key":"e_1_3_3_5_2","volume-title":"International Classification of Sleep Disorders.","author":"American Academy of Sleep Medicine","year":"2023","unstructured":"American Academy of Sleep Medicine . International Classification of Sleep Disorders. 3rd ed , text revision. Darien, IL : American Academy of Sleep Medicine ; 2023 .","edition":"3"},{"issue":"5","key":"e_1_3_3_6_2","first-page":"233","article-title":"The medical and economic burden of narcolepsy: implications for managed care","volume":"10","author":"Thorpy MJ","year":"2017","unstructured":"Thorpy MJ , Hiller G . The medical and economic burden of narcolepsy: implications for managed care . Am Health Drug Benefits. 2017 ; 10 ( 5 ): 233 \u2013 241 .","journal-title":"Am Health Drug Benefits."},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.sleep.2012.08.002"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.5664\/jcsm.9326"},{"key":"e_1_3_3_9_2","volume-title":"Xyrem\u00ae (Sodium Oxybate) Oral Solution, CIII [Prescribing Information].","year":"2023","unstructured":"Xyrem\u00ae (Sodium Oxybate) Oral Solution, CIII [Prescribing Information]. Palo Alto, CA : Jazz Pharmaceuticals, Inc .; 2023 ."},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6612a3"},{"key":"e_1_3_3_11_2","volume-title":"Dietary Reference Intakes for Sodium and Potassium.","author":"National Academies of Sciences Engineering and Medicine","year":"2019","unstructured":"National Academies of Sciences Engineering and Medicine . Dietary Reference Intakes for Sodium and Potassium. Washington, DC : National Academies Press ; 2019 ."},{"key":"e_1_3_3_12_2","unstructured":"Ben-Joseph RH Somers VK Black J et\u00a0al . Hypertension onset among narcolepsy patients newly treated with sodium oxybate. Poster 344 presented at: Annual Meeting of the Associated Professional Sleep Societies ; June 4\u20138 2022. Charlotte NC."},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.sleep.2016.04.004"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/zsad161"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/zsaa206"},{"key":"e_1_3_3_16_2","volume-title":"Xywav\u00ae (Calcium, Magnesium, Potassium, and Sodium Oxybates) Oral Solution, CIII [Prescribing Information].","year":"2023","unstructured":"Xywav\u00ae (Calcium, Magnesium, Potassium, and Sodium Oxybates) Oral Solution, CIII [Prescribing Information]. Palo Alto, CA : Jazz Pharmaceuticals, Inc .; 2023 ."},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199511093331917"},{"key":"e_1_3_3_18_2","unstructured":"US Food and Drug Administration . Clinical review for Binosto NDA 202344 . https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2012\/202344Orig1s000 MedR.pdf . Published 2012. Accessed February 28 2023."},{"key":"e_1_3_3_19_2","unstructured":"US Food and Drug Administration . Quantitative labeling of sodium potassium and phosphorus for human over-the-counter and prescription drug products . https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/quantitative-labeling-sodium-potassium-and-phosphorus-human-over-counter-and-prescription-drug . Published September 2022. Accessed October 11 2022."},{"key":"e_1_3_3_20_2","volume-title":"Lumryz\u2122 (Sodium Oxybate) for Extended-Release Oral Solution, CIII [Prescribing Information].","year":"2023","unstructured":"Lumryz\u2122 (Sodium Oxybate) for Extended-Release Oral Solution, CIII [Prescribing Information]. Chesterfield, MO : Avadel CNS Pharmaceuticals ; 2023 ."},{"key":"e_1_3_3_21_2","unstructured":"US Food and Drug Administration . Clinical superiority findings . Jazz Pharmaceuticals Ireland Limited for Xywav (calcium magnesium potassium and sodium oxybates). https:\/\/www.fda.gov\/industry\/designating-orphan-product-drugs-and-biological-products\/clinical-superiority-findings . Accessed July 9 2021."},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-022-00926-0"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.sleep.2023.05.023"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.sleep.2023.11.022"},{"key":"e_1_3_3_25_2","volume-title":"International Classification of Sleep Disorders.","author":"American Academy of Sleep Medicine","year":"2014","unstructured":"American Academy of Sleep Medicine . International Classification of Sleep Disorders. 3rd ed . Darien, IL : American Academy of Sleep Medicine ; 2014 .","edition":"3"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890425596"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/14.6.540"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.sleep.2021.06.008"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.sleep.2023.10.029"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/zsad077.0587"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.smrv.2021.101440"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b4567"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.111.641043"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1311989"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)11911-8"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39147.604896.55"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2105675"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200101043440101"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0000000000001733"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1701"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehac059"},{"key":"e_1_3_3_42_2","unstructured":"Jazz Pharmaceuticals expands support of the American Heart Association to raise awareness of the link between sleep disorders and heart health [press release]. https:\/\/www.prnewswire.com\/news-releases\/jazz-pharmaceuticals-expands-support-of-the-american-heart-association-to-raise-awareness-of-the-link-between-sleep-disorders-and-heart-health-301785799.html . Published March 30 2023. Accessed October 11 2023."}],"container-title":["Journal of Clinical Sleep Medicine"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T09:05:46Z","timestamp":1770109546000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.5664\/jcsm.11182"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":41,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["10.5664\/jcsm.11182"],"URL":"https:\/\/doi.org\/10.5664\/jcsm.11182","relation":{},"ISSN":["1550-9389","1550-9397"],"issn-type":[{"value":"1550-9389","type":"print"},{"value":"1550-9397","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9]]}}}